Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.37% | |
| Gapped Down | Weakness | 0.37% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.46% | |
| Inside Day | Range Contraction | -4.46% | |
| Wide Bands | Range Expansion | -4.46% | |
| Wide Bands | Range Expansion | -2.98% | |
| Down 3 Days in a Row | Weakness | -2.98% |
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| Possible Inside Day | about 15 hours ago |
| Up 1% | about 17 hours ago |
| Down 5% | 1 day ago |
| Gap Down Closed | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 11/06/2024
ACADIA Pharmaceuticals Inc. Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Medication Alzheimer's Disease Chemical Compounds Parkinson's Disease Chronic Pain Neurological Disorders Schizophrenia Central Nervous System Disorders Glaucoma Nervous System Disorders Treatment Of Parkinson's Disease Urological Disorders Treatment Of Glaucoma Treatment Of Alzheimer's Disease Treatment Of Chronic Pain Treatment Of Schizophrenia Psychosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.59 |
| 52 Week Low | 14.15 |
| Average Volume | 1,375,693 |
| 200-Day Moving Average | 17.34 |
| 50-Day Moving Average | 15.61 |
| 20-Day Moving Average | 15.99 |
| 10-Day Moving Average | 17.20 |
| Average True Range | 0.64 |
| RSI (14) | 51.92 |
| ADX | 24.44 |
| +DI | 26.85 |
| -DI | 24.87 |
| Chandelier Exit (Long, 3 ATRs) | 16.80 |
| Chandelier Exit (Short, 3 ATRs) | 16.06 |
| Upper Bollinger Bands | 18.62 |
| Lower Bollinger Band | 13.36 |
| Percent B (%b) | 0.55 |
| BandWidth | 32.86 |
| MACD Line | 0.45 |
| MACD Signal Line | 0.45 |
| MACD Histogram | 0.0002 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.77 | ||||
| Resistance 3 (R3) | 16.76 | 16.57 | 16.69 | ||
| Resistance 2 (R2) | 16.57 | 16.44 | 16.58 | 16.66 | |
| Resistance 1 (R1) | 16.42 | 16.36 | 16.50 | 16.44 | 16.63 |
| Pivot Point | 16.24 | 16.24 | 16.27 | 16.24 | 16.24 |
| Support 1 (S1) | 16.09 | 16.11 | 16.16 | 16.10 | 15.91 |
| Support 2 (S2) | 15.90 | 16.03 | 15.91 | 15.88 | |
| Support 3 (S3) | 15.75 | 15.90 | 15.85 | ||
| Support 4 (S4) | 15.77 |
